Contact Us
Keep me updated
PMBC 2018
Menu
Home
Congress Information
General Information
Congress Chair
Welcome Note
Program
Congress Program
Workshop: Liquid Biopsy Beyond Cancer
Congress Speakers
Congress Aims
Registration & Accommodation
Registration
Accommodation
Invitation Letter
Sponsorship & Exhibition
Sponsorship & Exhibition Opportunities
Start-Ups
Sponsor & Exhibitor Profiles
Media Partners
Contact Us
Contact Us
Join Our Newsletter
Home
Congress Information
General Information
Congress Chair
Welcome Note
Program
Congress Program
Workshop: Liquid Biopsy Beyond Cancer
Congress Speakers
Congress Aims
Registration & Accommodation
Registration
Accommodation
Invitation Letter
Sponsorship & Exhibition
Sponsorship & Exhibition Opportunities
Start-Ups
Sponsor & Exhibitor Profiles
Media Partners
Contact Us
Contact Us
Join Our Newsletter
Congress Aims
Who will Dominate Healthcare & Medicine
Next generation business models amid value-based compensation
Customers versus patient engagement
How will the payer, provider role change
Data Sciences
AI a hyped buzzword
Machine/Deep Learning
Topological data analysis
Validating “black box” analytics
Garbage in – garbage out
Clinical research & development
Next generation clinical trials, N-of-1, longitudinal trials as an emerging paradigm
“Virtual” or remote clinical trials, sensors
Real World studies
Rare diseases as role models for large indications; how to
Choose the best end point study that provides answers and that has a high probability of achievement
Design studies that provide high quality data and can be used for decision making
Include criteria that enable fast recruitment of patients; Choose design elements and inclusion/exclusion criteria that increase the probability of success for the study
Ensure the best retention rate
Regulatory Process, Data Safety & Security
Machine/Deep Learning, next generation “biomarkers”
Help the regulatories develop a fast track approval for clinical studies on all levels (EMA/FDA, Country level, Institute level)
Encourage off label to label studies
Enable collaboration between regulatories, payers, industry and academia, to ensure high probability of successful drug marketing
Implementing GDPR
Design RCT’s using electronic charts
Use electronic chart to study real world efficacy and safety of drugs and device
Financing Disruption
Who should found necessary moonshots
VCs, impact investors, payers and government roles
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies.
Got it!